Astoria Biologica — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Astoria Biologica is a private, preclinical-stage biotech focused on autoimmune and inflammatory diseases, particularly Multiple Sclerosis. The company employs a biologics and antibody-based therapeutic approach to develop novel treatments. As a young, venture-backed firm, it is in the early stages of research and development, positioning itself in a high-need, high-value therapeutic market. Its success will hinge on advancing its pipeline into clinical trials and securing strategic partnerships or further funding.

Autoimmune DiseasesInflammatory DiseasesMultiple Sclerosis

Technology Platform

Platform for developing novel biologics and antibody-based therapeutics, potentially combining insights from small molecule and protein engineering.

Opportunities

The large and growing market for Multiple Sclerosis and autoimmune therapies presents a significant commercial opportunity.

A successful novel biologic could address unmet needs for safer, more effective treatments.

The company's platform could also be leveraged to expand into other high-value inflammatory indications.

Risk Factors

High scientific risk that novel biologics will fail in preclinical or clinical development.

Significant funding risk as a pre-revenue company dependent on venture capital.

Intense competition from large pharma and other biotechs in the autoimmune space.

Competitive Landscape

The Multiple Sclerosis and autoimmune disease market is highly competitive, dominated by large pharmaceutical companies with extensive portfolios. Astoria Biologica will compete against both established blockbuster therapies and a pipeline of novel mechanisms from other biotechs, necessitating a clear differentiation in efficacy or safety.

More companies in Small Molecule Drugs →More companies in United States →